| |
Report |
Presentation |
Webcast |
|
December 2, 2021
Oasmia - Presentation Erik Penser Bank
|
|
|
|
|
December 2, 2021
Presentation at Stora Aktiedagen Stockholm
|
|
|
|
|
November 18, 2021
Interim Report January – September 2021
|
|
|
|
|
October 21, 2021
Interview Erik Penser Bank
|
|
|
|
|
September 29, 2021
Naventus LifeScience Summit
|
|
|
|
|
September 7, 2021
Presentation at Aktiedagen Stockholm
|
|
|
|
|
August 19, 2021
Interim Report January – June 2021
|
|
|
|
|
June 11, 2021
Aktiespararna: Interview with Oasmia Pharmaceutical
|
|
|
|
|
May 27, 2021
Interim Report January – March 2021
|
|
|
|
|
April 29, 2021
Annual Report 2020
|
|
|
|
|
April 12, 2021
Cantrixil abstract from Final Phase I Data at the 2021 AACR Annual Meeting
|
|
|
|
|
March 21, 2021
BioEurope Spring, Virtual
|
|
|
|
|
March 11, 2021
Sachs 14th Annual European Life Sciences CEO Forum, Virtual
|
|
|
|
|
March 1, 2021
Oasmia acquires global development and commercialization rights for Cantrixil
|
|
|
|
|
February 19, 2021
Year-end report 2020
|
|
|
|
|
February 10, 2021
Swiss Nordic Bio
|
|
|
|
|
January 19, 2021
SEB Digital Healthcare Seminar Presentation
|
|
|
|
